Bruce Pharriss, PhD, the company's founder and former chairman and CEO, dies Sept. 8 of cancer, the Santa Clara, Calif. firm reports Sept. 9. Pharriss was 55. Celtrix announced on Aug. 31 that, due to Pharriss' health, Dale Stringfellow, PhD, was assuming the CEO duties. Stringfellow, 48, has been president of Celtrix since 1990. Celtrix Director Roger Salquist, 51, will serve as chairman. Salquist is chairman of Calgene and vice chairman of the Biotechnology Industry Organization. In early June, Celtrix closed a private placement of 1.8 mil. shares of common stock, resulting in gross proceeds of $10.5 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: